Phase 4 N=52 Contralateral ReSTOR / Monofocal or Phakic Eye
Cataracts
Primary: Visual Acuity — -0.04; -0.01; 0.14; 0.18 LogMar
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=40 Clinical Outcomes With Bilateral Implantation of Odyssey IOLs
Cataract
Primary: Visual Acuity at Distance (6m) logMAR — 0.00; -0.02; 0.02; 0.00 logMAR
N/A N=30 AcrySof® Bilateral PanOptix(R) Spectacle Freedom and Patient Satisfaction Study
Cataract
Primary: Number of Participants Who Have Spectacle Independence — 27 Participants
Phase 4 N=76 Visual Function After Implantation of Bilateral AcrySoft ReSTOR Aspheric IOL
Cataract
Primary: Visual Acuity — 0.54; 0.06; 0.03; 0.04 logMAR
N/A N=80 Quatera 700 vs. Centurion
Cataract
Primary: Central Corneal Thickness — 572.8; 565.6 microns
Phase 4 N=34 Visual Function With Bilateral AcrySof® ReSTOR® Aspheric SN6AD1
Cataract
Primary: Binocular Visual Acuity at Distance, Near and Intermediate — 0.00; 0.13; 0.07; 0.00 LogMAR
N/A N=25 A Comparison of Visual Function After Bilateral Implantation of Presbyopia-Correcting Intraocular Lenses (IOLs)
Cataract
Primary: Mean Binocular Defocus VA at Month 3 — 0.78; 0.59; 0.65; 0.45 logMAR
N/A N=442 Cerebrotendinous Xanthomatosis (CTX) Prevalence Study
Cerebrotendinous Xanthomatosis (CTX)
Primary: Number of Participants Who Had Positive Genetic Test Results — 4 Participants
Phase 4 N=60 Visual Function After Bilateral Implantation of AcrySof® Toric
Visual Function
Primary: Uncorrected Visual Acuity (UCVA) — 0.06; 0.14 logMAR
N/A N=103 A Clinical Outcome Study of Two Multifocal Intraocular Lenses (IOL) in Cataract Patients
Cataracts
Primary: Binocular Distance Corrected Visual Acuity (logMAR) - Intermediate (60 cm) — 0.13; 0.09 logMAR
Phase 3 N=211 Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
Cataract
Primary: Anterior Chamber Cell Grade — 67; 18 Participants
Phase 3 N=126 Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
Cataract
Primary: Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero — 28; 20 Participants
Phase 3 N=156 Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
Cataract
Primary: Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero — 36; 23 participants
Phase 3 N=215 Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)
Cataract
Primary: Anterior Chamber Cell Grade — 38; 7 Participants
Phase 2 N=121 A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
Allergic Conjunctivitis
Primary: Ocular Itching — 1.908; 1.925; 1.177; 2.758 units on a scale — p=0.0002
Phase 4 N=79 Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery
Cystoid Macular Edema
Primary: Central Macular Thickness (Difference in Mean Pre-post Changes by the Two Treatment Groups) — 2.78; 5.6 microns — p=0.7029
Phase 4 N=218 Visual Function After Implantation of Bilateral AcrySof ReSTOR Aspheric +3
Cataract
Primary: Uncorrected Visual Acuity (UCVA) — 0.05; -0.07; 0.15; 0.20 logMAR
N/A N=229 Toric Intraocular Lens Following Cataract Surgery
Cataract · Astigmatism
Primary: Percent Reduction in Absolute Cylinder — 84.975; 46.498 percentage of intended cylinder reduct
N/A N=114 Infant Aphakia Treatment Study (IATS)
Congenital Cataract
Primary: Visual Acuity — 0.80; 0.97 logMAR units — p=0.19
Phase 4 N=94 No Drop Post-Op Cataract Surgery
Cataract
Primary: Best Corrected Visual Acuity (BCVA) (Pre-op) — .28 LogMar
Phase 3 N=181 Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery
Cataract
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 53; 13; 1; 0 Participants
Phase 4 N=64 A Comparison of Visual Function After Bilateral Implantation of Presbyopia-correcting Intraocular Lenses (IOLs)
Cataract
Primary: Defocus Curve — 0.585; 0.653; 0.490; 0.475 LogMAR
Phase 4 N=20 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema
Macular Edema, Cystoid · Vision Disorders · Diabetic Macular Edema
Primary: Change in the Central Macular Thickness — 85.67; -18.22 Microns
N/A N=30 Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens
Cataract
Primary: Binocular Distance-corrected Near (40 cm) Visual Acuity — 0.00 logMAR
N/A N=100 Posterior Capsule Opacification and Frequency of Nd:YAG Treatment and of Two Microincision IOLs: Hoya iMics NY-60 vs Acrysof SN60WF
Capsule Opacification · Pseudophakia · Cataract
Primary: Posterior Capsule Opacification (PCO) — 3.0; 1.9 units on a scale (0-10)
N/A N=104 Posterior Capsule Opacification (PCO) Evaluation of the AcrySof SN60AT Lens vs. SN60WF Lens
Cataract
Primary: Posterior Capsule Opacification (PCO) — 11.58; 14.04 Percentage of PCO
Phase 4 N=34 Visual Function Evaluation of Bilateral AcrySof ReSTOR Aspheric IOL
Cataracts
Primary: Uncorrected and Best Corrected Visual Acuities (Near and Distance) — 0.02; 0.01; 0.00; -0.03 logMAR
Phase 3 N=122 One-Piece Hydrophobic Acrylic Intraocular Lens in Subjects Undergoing Cataract Extraction
Aphakia · Cataract
Primary: Visual Acuity — 108 Participants
N/A N=117 A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice
Cataracts · Meibomian Gland Dysfunction (MGD)
Primary: Mean Monocular UCDVA (Uncorrected Distance Visual Acuity) — 0.08; 0.07 LogMAR
N/A N=15 ACRYSOF® Toric NATURAL T9 Intraocular Lens (IOL)
Bilateral Cataract
Primary: Number of Subjects Reporting Spatial Distortions Related to Intraocular Lens (IOL) Misalignment — 11; 2 Participants